Can afamelanotide and polymyxin B be used together?

Yes, theoretically they could be co-prescribed—they work on entirely different systems and don't interact. However, the scenarios that call for both are rare: an EPP patient with a serious multidrug-resistant infection would be an unusual case. Most EPP patients won't need polymyxin B; most infection patients won't need afamelanotide.

Why isn't polymyxin B approved by the EMA?

The EMA has preferred alternative agents and stricter thresholds for antibiotic approvals. Polymyxin B's toxicity profile—particularly nephrotoxicity—led regulators in Europe to rely on other options. It remains available in the US and Canada where clinical need is recognized.

Is afamelanotide a permanent treatment for EPP?

No. The implant lasts about 2 months, after which efficacy wanes. Patients require re-implantation if they wish to maintain increased melanin levels. However, the treatment is reversible—discontinuing it doesn't cause harm.

What happens if someone uses polymyxin B long-term?

Long-term polymyxin B use significantly increases the risk of kidney and nerve damage. It's reserved for serious infections when alternatives aren't available, usually for days to weeks, not months. Careful monitoring of kidney function is mandatory.

Are there newer alternatives to either compound?

For EPP, afamelanotide remains the standard peptide treatment, though other approaches (sunscreens, protective clothing, light therapy) are also used. For resistant gram-negative infections, newer agents like ceftazidime-avibactam and newer carbapenems have emerged, though polymyxin B remains valuable when these fail.

Afamelanotide vs Polymyxin B: Key Differences

Afamelanotide and polymyxin B are both FDA-approved compounds, but they work in completely different ways and treat different conditions. Afamelanotide is a synthetic peptide that stimulates melanin production and is approved for treating erythropoietic protoporphyria (EPP), a rare photosensitivity disorder. Polymyxin B, by contrast, is an antibiotic that disrupts bacterial cell membranes and is used to treat serious infections caused by gram-negative bacteria. They're not interchangeable—each addresses a distinct medical need. This guide breaks down what they are, how the evidence stacks up, their regulatory standing, and which might be relevant depending on the condition being addressed.

What Is Afamelanotide?

Afamelanotide is a synthetic peptide—a short chain of amino acids—that mimics alpha-melanocyte-stimulating hormone (α-MSH), a natural signaling molecule in the body. It's designed to activate melanocortin-1 receptors on melanocytes (the cells that produce skin pigment), triggering increased melanin production.

The compound is FDA-approved and EMA-authorised specifically for erythropoietic protoporphyria (EPP), a rare genetic disorder in which people experience severe photosensitivity and painful phototoxic reactions upon sun exposure. Afamelanotide is administered as a subcutaneous implant—a small pellet inserted under the skin that releases the peptide gradually over about two months.

The mechanism is straightforward: more melanin = more protection against harmful UV radiation, which reduces the debilitating pain and blistering that EPP patients experience outdoors. Clinical evidence shows that afamelanotide significantly reduces phototoxic reaction severity and improves quality of life for patients, with 23 registered clinical trials examining its safety and efficacy.

What Is Polymyxin B?

Polymyxin B is a cyclic peptide antibiotic that works through a fundamentally different mechanism: it disrupts the outer cell membrane of gram-negative bacteria, causing cell lysis and death. It's been used clinically for over 60 years, primarily as a last-line antibiotic for serious infections caused by multidrug-resistant gram-negative pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae.

Polymyxin B is FDA-approved and Health Canada-approved, though notably not authorised by the EMA in Europe. It's typically reserved for patients with infections that resist other antibiotics, including carbapenem-resistant organisms. 66 clinical trials have evaluated its use across various infection types and populations.

Polymyxin B can be administered intravenously, intramuscularly, or topically depending on the infection site and severity.

Mechanism of Action: Completely Different

This is the clearest distinction: Afamelanotide is a signaling peptide; polymyxin B is a bactericidal antibiotic. Afamelanotide works by hijacking your body's own melanin production system to increase skin protection. Polymyxin B works by chemically destroying bacterial cell membranes—it has no effect on human cells because of structural differences in how cell membranes are organized.

This is why comparing them side-by-side doesn't make practical sense: you wouldn't choose between them. The condition being treated determines which is relevant.

Clinical Evidence and Trial Data

Afamelanotide: With 23 registered clinical trials, the evidence base for afamelanotide is moderately robust. Key trials have demonstrated that afamelanotide implants reduce phototoxic reactions in EPP patients by approximately 30-70% depending on dose and individual response. Most trials are small (EPP is rare, affecting roughly 1 in 50,000–200,000 people), but the primary endpoint—reduction in phototoxic reaction severity—is consistently met. Patients also report meaningful improvements in sun exposure tolerance and quality of life.

The evidence grade is A, indicating high-quality randomized controlled trials.

Polymyxin B: Polymyxin B has 66 registered clinical trials, reflecting decades of clinical experience and extensive research into its use in nosocomial and gram-negative infections. Clinical literature confirms its bactericidal activity against resistant gram-negative organisms, though its use is tempered by concerns about nephrotoxicity (kidney damage) and neurotoxicity, particularly at higher doses or in patients with renal impairment. Modern trials increasingly compare it with newer agents like colistin and newer beta-lactams to define its optimal role.

The evidence grade is also A, reflecting robust clinical trial data and decades of real-world use.

Regulatory Status

| Regulator | Afamelanotide | Polymyxin B | |-----------|---------------|-------------| | FDA (US) | Approved (2014) | Approved | | EMA (EU) | Authorised (2014) | Not authorised | | Health Canada | Not approved | Approved |

Afamelanotide has symmetrical approvals in the US and EU, reflecting coordinated review and agreement on its benefit-risk profile for a well-defined rare disease. Polymyxin B's absence from the EMA reflects historical preference for alternative agents in Europe and stricter threshold for antibiotic approvals; it remains available in Canada and the US where clinical need is recognized.

Key Differences at a Glance

Indication:

Afamelanotide: rare photosensitivity disorder (EPP)
Polymyxin B: serious gram-negative bacterial infections

Drug Class:

Afamelanotide: melanocortin receptor agonist peptide
Polymyxin B: bactericidal antibiotic peptide

Administration:

Afamelanotide: subcutaneous implant (every ~2 months)
Polymyxin B: IV, IM, or topical depending on infection

Duration of Effect:

Afamelanotide: weeks to months (sustained-release)
Polymyxin B: hours to days (depends on dose and route)

Toxicity Profile:

Afamelanotide: Generally well-tolerated; adverse events usually mild to moderate (nausea, headache, site reactions)
Polymyxin B: Dose-dependent nephrotoxicity and neurotoxicity are major concerns, especially in renal impairment

Who Each Is Best Suited For

Afamelanotide is appropriate for:

Patients with erythropoietic protoporphyria who experience recurrent phototoxic reactions despite rigorous sun avoidance and other protective measures. It's most useful in patients who want to expand their sun exposure tolerance and improve quality of life. The long-acting implant format suits people who prefer less frequent interventions. Because it's a peptide that mimics a natural hormone, it has a favorable safety profile compared to systemic treatments.

See also: Melanotan II for comparison with other melanocortin agonists.

Polymyxin B is appropriate for:

Patients with documented or suspected serious infections caused by multidrug-resistant gram-negative bacteria, particularly when no suitable alternative antibiotics are available. It's reserved for hospitalized patients where monitoring for nephrotoxicity and neurotoxicity is feasible. It's especially valuable against carbapenem-resistant Acinetobacter baumannii and resistant Pseudomonas. Polymyxin B is not first-line for most infections—it's a tool for resistant organisms.

See also: Colistin as an alternative polymyxin antibiotic, and Tobramycin as an adjunct aminoglycoside.

Evidence Quality and Real-World Use

Both compounds have strong evidence bases (Grade A), but they're rooted in very different trial designs. Afamelanotide trials are relatively small because EPP is rare, but they're well-controlled and patient-centered. Polymyxin B has larger, more numerous trials because infection is common; much of the evidence comes from observational studies and real-world cohorts due to ethical constraints on randomization (withholding treatment for seriously ill patients).

In clinical practice, afamelanotide is prescribed by dermatologists and specialists in porphyria centers; polymyxin B is prescribed by infectious disease specialists and intensivists in hospital settings.

Safety and Tolerability

Afamelanotide: Adverse events are mostly mild: nausea, headache, fatigue, and local reactions at the implant site. Serious adverse events are rare. The peptide is largely metabolized and doesn't accumulate. It's contraindicated in patients with melanoma or a history of melanoma due to theoretical concerns about stimulating melanocyte growth, though real-world data have not confirmed increased melanoma risk.

Polymyxin B: Nephrotoxicity (increased creatinine, reduced GFR) occurs in 30-60% of patients and is the primary limitation. Neurotoxicity (peripheral neuropathy, dizziness, confusion) occurs less frequently. Both are dose- and duration-dependent and often reversible if the drug is stopped. Baseline renal function and careful dosing adjustment are essential. Ototoxicity (hearing loss) is possible but rare.

Cost and Accessibility

Afamelanotide is expensive because it's a specialized peptide for a rare disease and requires a subcutaneous implantation procedure. It's generally covered by insurance in the US and EU for its approved indication, though copays and out-of-pocket costs vary.

Polymyxin B is relatively inexpensive as an older antibiotic, but its cost is dwarfed by the costs of ICU care and prolonged hospitalization for serious infections. It's widely available in hospital formularies.

Common Misconceptions

Misconception 1: "These are both peptide antibiotics, so they're similar." Reality: Both are peptides, but that's where the similarity ends. Afamelanotide is a signaling hormone mimic; polymyxin B is a bactericidal agent. Their pharmacology, uses, and safety profiles are entirely different.

Misconception 2: "Polymyxin B would work for sun sensitivity." Reality: Polymyxin B has no effect on melanin production or skin protection. It only works on bacteria.

Misconception 3: "Afamelanotide would help with serious infections." Reality: Afamelanotide has no antimicrobial activity and would not treat an infection.

For related melanin research, see Melanotan I.

For related antibiotic comparisons, see Polymyxin E (Colistin).

Afamelanotide vs Polymyxin B: A Head-to-Head Comparison